dc.contributor.author |
Nomura S. |
|
dc.contributor.author |
Egawa Y. |
|
dc.contributor.author |
Urano S. |
|
dc.contributor.author |
Tahara T. |
|
dc.contributor.author |
Watanabe Y. |
|
dc.contributor.author |
Tanaka K. |
|
dc.date.accessioned |
2021-02-25T20:56:18Z |
|
dc.date.available |
2021-02-25T20:56:18Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/162731 |
|
dc.description.abstract |
© 2020, The Author(s). In the field of molecular imaging, selectivity for target cells is a key determinant of the degree of imaging contrast. Previously, we developed a pre-targeted method by which target cells could be selectively imaged using a labeled N-glycan that was ligated in situ with an integrin-targeted cyclic RGD peptide on the cell surface. Here we demonstrate the power of our method in discriminating various cancerous and non-cancerous cells that cannot be distinguished using conventional RGD ligands. Using four cyclic RGDyK peptides with various linker lengths with five N-glycans, we identify optimal combinations to discriminate six types of αvβ3 integrin–expressing cells on 96-well plates. The optimal combinations of RGD and N-glycan ligands for the target cells are fingerprinted on the plates, and then used to selectively image tumors in xenografted mouse models. Using this method, various N-glycan molecules, even those with millimolar affinities for their cognate lectins, could be used for selective cancer cell differentiation. |
|
dc.title |
Cancer discrimination by on-cell N-glycan ligation |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
1 |
|
dc.relation.ispartofseries-volume |
3 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.source.id |
SCOPUS-2020-3-1-SID85080035643 |
|